Company: RCUS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001724521-25-000063
Chunk: 315

Company: Arcus Biosciences, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 315
---
 against us in connection with our storage or disposal of biological, hazardous or radioactive materials. 

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our R&D. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. 

Risks Related to Owning our Common Stock 

The stock price of our common stock has been and may continue to be volatile or may decline regardless of our operating performance.

The market price of our common stock has fluctuated and may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: 

•overall performance of the equity markets; 

58

•our operating performance and the performance of other similar companies; 

•results from our ongoing clinical trials and future clinical trials with our current and future investigational products or of our competitors; 

•changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; 

•regulatory, trade or legal developments in the U.S. and other countries, including changes in tariffs or other trade restrictions and the changes in the structure of healthcare payment systems; 

•the level of expenses related to future investigational products or clinical development programs; 

•our failure to achieve product development goals in the timeframe we announce; 

•announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; 

•recruitment or departure of key personnel; 

•the economy as a whole and market conditions in our industry; 

•trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; 

•the size of our market float; and 

•any other factors discussed in this report. 

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business. 

The amount of our future losses is uncertain and our quarterly operating